Diabetes Care 2022; online ahead of print doi: 10.2337/dc22-0294
Analysis of composite endpoint incidence suggested a trend toward lower risk with finerenone plus an SGLT2i at baseline; however, corresponding tests for interaction were not significant. Similarly, those with SGLT2i use at any time during the on-treatment period showed no clear differences in response to finerenone versus those who did not receive an SGLT2i.
The authors conclude that the benefits of finerenone compared with placebo on cardiorenal outcomes in patients with CKD and T2D were observed irrespective of SGLT2i use. These results build on findings from the FIDELIO-DKD trial that demonstrated a consistent reduction in UACR with finerenone irrespective of SGLT2i intake at baseline.